泽璟制药：关于自愿披露注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准通知书的公告

Core Points - Zai Jian Pharmaceutical has received approval from the National Medical Products Administration for a clinical trial of ZG006 in combination with Etoposide and Cisplatin for advanced neuroendocrine carcinoma [2] Group 1 - The clinical trial approval is a significant milestone for Zai Jian Pharmaceutical, indicating progress in its drug development pipeline [2] - The combination therapy aims to address a critical need in the treatment of advanced neuroendocrine cancer, which has limited treatment options [2]